Response to Sorafenib at a Low Dose in Patients with Radioiodine-Refractory Pulmonary Metastases from Papillary Thyroid Carcinoma

• DOI: 10.1089/thy.2010.0199
• Publication Date: 2010-12-27T18:01:42Z
• Authors: Libo Chen; Yan Shen; Quanyong Luo; Yongli Yu; Hankui Lu; Ruisen Zhu
• Keywords: Refractory (planetary science)

Background: Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma. However, optimal dose not been established and data on Chinese population are available. We conducted a study to assess responses sorafenib at low 200 mg twice daily progressive radioiodine-refractory pulmonary metastases from papillary carcinoma (PTC). Patients Methods: Eligible received orally daily. Responses were assessed using Response Evaluation Criteria Solid Tumors adverse events periodically. The end points included response rate progression-free survival. Results: Nine PTC enrolled treated for minimum 13 weeks. objective partial was 33%. stable disease 44%. mean survival 42 weeks (95% confidence interval, 29.5 53.9). Two showed progression, one them died 4 months after beginning treatment. There marked rapid change serum thyroglobulin level start treatment, decrease 60% within 12 weeks, consistent radiographic findings. Although types toxicities other trials, their severity relatively mild. None discontinued reduced because treatment-related events. Conclusion: potential therapeutic effect is well tolerated metastases. Further warranted larger cohort patients.